The FDA has recently approved the investigational new drug (IND) application for Nantheia ATL5. This has the potential to be an important breakthrough for those suffering from opioid use disorder (OUD).
Nantheia ATL5 is actually based on Ananda Scientific’s own Liquid Structure Technology. Through this cutting-edge technology, Ananda has been able to increase the effectiveness of CBD. They are achieving these impressive results while still keeping the CBD itself stable and safe.
All of this is leading to new and exciting ways that CBD can be utilized for therapeutics. One example of this is that Nantheia ATL5 may be able to reduce the required opioid intake for people who are in the process of being treated for OUD.
Sohail Saidi is the CEO of Ananda Scientifics. A recent statement from Saidi said “This is the fourth IND approval for our investigational drug Nantheia product line, and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications. This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need,”
The study at UCLA is being led by Richard De La Garza, PhD and Edythe London, PhD. Richard De La Garza is a professor of psychiatry and biobehavioral sciences. Edythe London also adds molecular and medicinal pharmacology to the knowledge base and vast expertise of the professors. They are both professors at the Jane and Terry Semel Institute at UCLA.
Opioids and Overdose
Sadly, there have been almost 841,000 drug overdose deaths in the United States since 1999. In 2019 alone there were over 70,000 drug overdose deaths. Out of those 70,000+ deaths in 2019, over 70% were a result of opioid overdose. Those are staggering numbers. They obviously paint a grim picture of opioid use in the United States.
Even more concerning is that the amount of drug overdose death in the most recent years has climbed even higher. In 2020 the CDC recorded 78,056 overdose deaths. In the 12 month period that ended in April 2021, the CDC estimated a staggering 100,306 drug overdose deaths in the United States.
That is why Ananda and Zaidi are on a mission to help people and they believe CBD has the ability to do that coupled with their patented delivery technology.
“This clinical trial with Nantheia ATL5 has the possibility to advance applications for CBD in ANANDA’s patented delivery technology in an area that could positively impact the lives of a large number of people suffering from opioid addiction. Opioids are a huge driver of overdose deaths in the U.S. and a non-addictive therapy is a significant unmet need,” Zaidi said.
These thousands of tragic deaths make one wonder what the route causes of the drug overdose problem could be. Admittedly, Nantheia ATL5 is not going to address and cure the root causes. But this CBD product could possibly help be part of the cure to help people struggling with drug addiction.